-
Achieves 2 Million Jeuveau® Redemptions
-
Anticipates Launch of Club Evolus
™
, the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Oct. 29, 2024--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program.
“The achievement of these milestones underscores the success of our strategy to democratize beauty and make aesthetics accessible to a new generation of consumers,” said David Moatazedi, President and Chief Executive Officer. “Our easy-to-use, SMS-based loyalty program offers consumers an instant $40 savings on every Jeuveau® treatment, while providing practices with the only co-branded solution to encourage repeat visits. We’re proud of the rapid adoption of this innovative program, which has grown to over 1 million consumers and achieved more than 2 million redemptions.
“We are excited to expand our loyalty offering with the upcoming launch of Club Evolus, the industry's first subscription-based consumer membership program from a neurotoxin manufacturer, debuting on November 4th. Powered by the same proprietary digital platform that enhances the practice experience, Club Evolus will offer consumers even more value and convenience.”
Evolus Rewards™ was launched in 2020 soon after Jeuveau® was approved by the FDA in 2019. The program offers enrolled patients $40 off Jeuveau® treatments every 90 days at participating providers. The program enhances convenience and ease by delivering a fun, frictionless experience with instant rewards. This approach allows both patients and practices to effortlessly engage with the program.
Evolus Rewards™ supports the company’s mission of partnering with its customers and driving consumers back to their practices with co-branded reminders and text messages, while attracting the next generation of beauty consumers considering aesthetic injectables. On average, practices participating in Evolus Rewards™ experience significantly higher revenue growth than non-participating practices.
Importantly, more than half of new entrants to Evolus Rewards™ are millennials or younger. This demographic represents the future of the aesthetics industry and is a highly sought-after audience for providers looking to expand their businesses.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20241029169655/en/
Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus, Inc.
